ZURICH (Reuters) –in their manufacturing.
“Novartis is conducting a thorough review of the situation and currently expects to resolve the issues and resume some supply in the next six weeks,” the Swiss company said.
The drugmaker added in a statement that some doses of cancer therapy Lutathera would be available in Europe and Asia from a site in Spain, but there might be some delays in supply.
Lutathera and Pluvicto are both so-called radioligand therapies. The U.S. Food and Drug Administration approved Pluvicto in March for treatment of prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC).
Lutathera was approved in 2018 to treat somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Reuters Health Information © 2022